{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-24-000050","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.374594+00:00","generated_at":"2026-05-30T08:36:08.313331+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Mineralys completes Launch-HTN enrollment ahead of schedule; topline data mid-H1 2025","bullets":["Enrollment completed ahead of schedule in global Phase 3 Launch-HTN trial of lorundrostat for uncontrolled or resistant hypertension.","Topline data now anticipated in mid first half of 2025, earlier than originally planned.","Trial randomized patients to placebo, lorundrostat 50 mg QD, or 50 mg titrated to 100 mg QD; primary endpoint SBP change at 6 weeks.","Company hosting virtual KOL event on Oct 30 to discuss unmet need and lorundrostat pivotal program."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-24-000050","json":"https://secwatch.observer/filing/0001933414-24-000050.json","markdown":"https://secwatch.observer/filing/0001933414-24-000050.md","text":"https://secwatch.observer/filing/0001933414-24-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000050/0001933414-24-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000050/mlys-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:36:08.313331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}